Adcendo funding boosts antibody-drug conjugates development
Funds will be used to ensure the wider pan-sarcoma development of lead candidate uPARAP
Read More
Tag: antibody
Spirea raises £2.4m to develop antibody drug conjugates in cancer
Funding will enable the development of Spirea’s pipeline of antibody drug conjugate therapeutics for the treatment of solid tumours
Read More
AstraZenca’s antibody cocktail Evusheld receives MHRA authorisation
Approval is significant as waning restrictions present significant threats to many immunocompromised people across the UK
Read More
GSK, Vir Bio start study of COVID-19 antibody therapy
The Phase II/III COMET-ICE study will assess safety and efficacy of antibody treatment in preventing hospitalisation due to COVID-19
Read More
Gov’t unveils coronavirus antibody testing scheme
10 million tests have so far have been secured in a ‘landmark deal’ with industry, including Roche Diagnostics and Abbott Labs
Read More
AbbVie discontinues Rova-T programme
An Independent Data Monitoring Committee recommended terminating the trial, following a failure to demonstrate survival benefit.
Read More
Cancer Research UK, Hummingbird join forces on anti-HER3 antibody drug
If successful, HMBD-001 could be used in the treatment of multiple cancers and be effective against drug resistant cancers.
Read More
New Herceptin combo could keep breast cancers at bay
Guiding chemotherapy to a tumour by attaching it to the antibody-based target drug Herceptin is effective at treating women with breast cancer who have no other treatment options.
Read More
AbCellera collaborates with Novartis for antibody discovery
AbCellera has announced a multi-target, multi-year deal with Novartis, to identify antibodies for ten therapeutic targets in Novartis’ pipeline, using a unique combination of microfluidics, high-throughput imaging, genomics, deep computing and AI.
Read More
UK’s MRC Tech licenses antibody to Chinese group
UK medical research charity MRC Technology has licensed an antibody to Newsummit Biopharma, a leading China-based drug development process solutions provider, for development of a novel therapeutic for treatment of Hepatitis C virus infection.
Read More
- Fabentech secures French approval for Ricimed antidote
- Oxford Drug Design reports major in vivo milestone for novel cancer therapy
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
